What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Prostate cancer
The scientist’s investigation covers issues in Prostate cancer, Internal medicine, Oncology, Surgery and Prostate-specific antigen.
His Prostate cancer study combines topics in areas such as Clinical trial, Gynecology, Disease and Docetaxel.
His research links Endocrinology with Internal medicine.
His Oncology research includes themes of Darolutamide, Cabazitaxel and Pathology.
His Surgery research incorporates themes from Placebo and Hazard ratio.
His Prostate-specific antigen study incorporates themes from Prostatectomy and Bone metastasis.
His most cited work include:
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer (1817 citations)
- Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group (925 citations)
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. (709 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Prostate cancer, Internal medicine, Oncology, Docetaxel and Cancer.
His research on Prostate cancer often connects related areas such as Urology.
His studies deal with areas such as Gynecology and Surgery as well as Internal medicine.
Oliver Sartor is involved in the study of Surgery that focuses on Randomized controlled trial in particular.
His study looks at the relationship between Oncology and topics such as Prostatectomy, which overlap with Androgen deprivation therapy.
Oliver Sartor has included themes like Mitoxantrone and Prednisone in his Docetaxel study.
He most often published in these fields:
- Prostate cancer (69.33%)
- Internal medicine (61.90%)
- Oncology (51.05%)
What were the highlights of his more recent work (between 2018-2021)?
- Prostate cancer (69.33%)
- Internal medicine (61.90%)
- Oncology (51.05%)
In recent papers he was focusing on the following fields of study:
Oliver Sartor spends much of his time researching Prostate cancer, Internal medicine, Oncology, Cancer and Enzalutamide.
His Prostate cancer research incorporates themes from Cancer research and Disease.
His research in Oncology intersects with topics in Radiation therapy, Incidence, Post-hoc analysis, Circulating tumor DNA and Genetic testing.
The study incorporates disciplines such as Abiraterone acetate and Prednisone in addition to Enzalutamide.
In his work, Prostate-specific antigen is strongly intertwined with Urology, which is a subfield of Radium-223.
He works mostly in the field of Docetaxel, limiting it down to topics relating to Cabazitaxel and, in certain cases, Quality of life, as a part of the same area of interest.
Between 2018 and 2021, his most popular works were:
- Olaparib for metastatic castration-resistant prostate cancer (222 citations)
- Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented] (88 citations)
- Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines. (66 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Prostate cancer
His primary areas of investigation include Prostate cancer, Internal medicine, Oncology, Cancer research and Enzalutamide.
His Prostate cancer research is multidisciplinary, incorporating perspectives in Immunotherapy and Hazard ratio.
The Docetaxel, Clinical trial, Progression-free survival and Genetic testing research Oliver Sartor does as part of his general Internal medicine study is frequently linked to other disciplines of science, such as Extramural, therefore creating a link between diverse domains of science.
His Clinical trial study integrates concerns from other disciplines, such as Castration resistant and Survival analysis.
His Oncology research includes elements of Prostate-specific antigen, Circulating tumor DNA, Cohort and Consensus conference.
Oliver Sartor has researched Cancer research in several fields, including Neurofibromin 1, Gene, Germline, Somatic cell and Androgen receptor.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
